Reference,Vaccine,Intervention_category,Country,N,Age_m,Age_formatted,Vaccine_formatted,Study_vaccines_original,Intervention_formatted,Intervention,Control_formatted,Control,Measure_of_SC,Int_SC_n,Int_N,Int_SC_perc,Int_SC_full,Ctrl_SC_n,Ctrl_N,Ctrl_SC_perc,Ctrl_SC_full,TotalBruckner (2016),Cholera,Antihelminthic,Gabon,105,7.4,7.4,2x WC-rBS,"WC-rBS (2 doses D0, 7)",Albendazole (400mg),Albendazole (400mg),Placebo,Placebo,Cholera-specific IgG,18,38,47%,18/38 (47%),17,33,52%,17/33 (52%),71Cooper (2000),Cholera,Antihelminthic,Ecuador,233,9,9,1x CVD103-HgR,CVD 103-HgR (1 dose D37),Albendazole (400mg),Albendazole (400mg),Placebo,Placebo,Vibriocidal AB,22,75,29%,22/75 (29%),10,64,16%,10/64 (16%),139Ahmed (Jan 2009),Cholera,Breastfeeding withheld,Bangladesh,176,7.5,7.5,2x WC-rBS,"WC-rBS (6ml) with buffer (2 doses, 2w apart)",W/h BF (3h),Witholding breastfeeding (3h before),U/r BF,U/r BF,Vibriocidal AB,18,33,55%,18/33 (55%),27,47,57%,27/47 (57%),80Ahmed (Jan 2009),Cholera,Breastfeeding withheld,Bangladesh,164,14,14,2x WC-rBS,"WC-rBS (6ml) with buffer (2 doses, 2w apart)",W/h BF (3h),Witholding breastfeeding (3h before),U/r BF,U/r BF,Vibriocidal AB,24,31,77%,24/31 (77%),27,49,55%,27/49 (55%),80John (1976),Polio,Breastfeeding withheld,India,302,1.5 - 12.75,1.5--12.8,3x tOPV,"tOPV (3 doses, 2,3,4m)",W/h BF (10h),Witholding breastfeeding (10h),U/r BF,U/r BF,OPV1 N-AB,10,17,59%,10/17 (59%),11,18,61%,11/18 (61%),35John (1976),Polio,Breastfeeding withheld,India,302,1.5 - 12.75,1.5--12.8,3x tOPV,"tOPV (3 doses, 2,3,4m)",W/h BF (10h),Witholding breastfeeding (10h),U/r BF,U/r BF,OPV2 N-AB,16,17,94%,16/17 (94%),18,18,100%,18/18 (100%),35John (1976),Polio,Breastfeeding withheld,India,302,1.5 - 12.75,1.5--12.8,3x tOPV,"tOPV (3 doses, 2,3,4m)",W/h BF (10h),Witholding breastfeeding (10h),U/r BF,U/r BF,OPV3 N-AB,11,17,65%,11/17 (65%),13,18,72%,13/18 (72%),35Ali (2015),Rotavirus,Breastfeeding withheld,Pakistan,400,1.4,1.4,3x RV1,"RV1 (3 doses, 6,10,14w)",W/h BF (2h),Witholding breastfeeding (1h before & after),U/r BF,U/r BF,Rotavirus IgA AB,51,181,28%,51/181 (28%),65,172,38%,65/172 (38%),353Ali (2015),Rotavirus,Breastfeeding withheld,Pakistan,400,1.4,1.4,2x RV1,"RV1 (2 doses, 6 & 10w)",W/h BF (2h),Witholding breastfeeding (1h before & after),U/r BF,U/r BF,Rotavirus IgA AB,30,181,17%,30/181 (17%),50,172,29%,50/172 (29%),353Groome (2014),Rotavirus,Breastfeeding withheld,South Africa,250,1.4*,1.4,2x RV1,"RV1 (2 doses, 6 & 14w)",W/h BF (2h),Witholding breastfeeding (1h before & after),U/r BF,U/r BF,Rotavirus IgA AB,62,98,63%,62/98 (63%),63,106,59%,63/106 (59%),204Rongsen (2014),Rotavirus,Breastfeeding withheld,India,400,1.6,1.6,2x RV1,"RV1 (2 doses, 6-7w & 10-14w)",W/h BF (30m),Witholding breastfeeding (30min before & after),U/r BF,U/r BF,Rotavirus IgA AB,45,172,26%,45/172 (26%),49,184,27%,49/184 (27%),356Ahmed (Jan 2009),Cholera,Buffer,Bangladesh,176,7.5,7.5,2x WC-rBS,"WC-rBS (2 doses, 2w apart)",20ml buffer,Buffer (20ml) standard bicarbonate,No buffer,No buffer,Vibriocidal AB,28,49,57%,28/49 (57%),7,16,44%,7/16 (44%),65Ahmed (Jan 2009),Cholera,Buffer,Bangladesh,164,14,14,2x WC-rBS,"WC-rBS (2 doses, 2w apart)",20ml buffer,Buffer (20ml) standard bicarbonate,No buffer,No buffer,Vibriocidal AB,27,49,55%,27/49 (55%),6,16,38%,6/16 (38%),65Sack (1997) *,Cholera,Buffer,USA,39,Adult,Adult,1x OCV Peru-15,OCV Peru-15 (1 dose),150ml buffer,"Buffer (150ml) Alka-Seltzer (sodium & potassium bicarbonate, citric acid)",No buffer,Standard buffer (sodium bicarbonate + ascorbic acid),Vibriocidal AB,10,10,100%,10/10 (100%),4,9,44%,4/9 (44%),19Trach (2002),Cholera,Buffer,Vietnam,143,251,Adult,2x biv-WC,"biv-WC (2 doses, 2w apart)",150ml buffer,Buffer (150ml) - sodium bicarbonate,No buffer,No buffer,Vibriocidal AB,20,35,57%,20/35 (57%),19,35,54%,19/35 (54%),70Chandir (2014),Polio,Buffer,Bangladesh,300,6.3*,6.3,3x tOPV,"tOPV (6,10,14w as per EPI)",5ml buffer,Buffer (5ml) sodium bicarboate + citrate at pH 8.86,No buffer,No buffer,OPV1 N-AB,125,132,95%,125/132 (95%),114,129,88%,114/129 (88%),261Chandir (2014),Polio,Buffer,Bangladesh,300,6.3*,6.3,3x tOPV,"tOPV (6,10,14w as per EPI)",5ml buffer,Buffer (5ml) sodium bicarboate + citrate at pH 8.86,No buffer,No buffer,OPV2 N-AB,126,132,95%,126/132 (95%),125,129,97%,125/129 (97%),261Chandir (2014),Polio,Buffer,Bangladesh,300,6.3*,6.3,3x tOPV,"tOPV (6,10,14w as per EPI)",5ml buffer,Buffer (5ml) sodium bicarboate + citrate at pH 8.86,No buffer,No buffer,OPV3 N-AB,119,132,90%,119/132 (90%),115,129,89%,115/129 (89%),261Ceyhan (1993),Rotavirus,Buffer,Turkey,205,1.0 - 3.0,1--3,1x RRV-TV,RRV-TV (1 dose),30ml buffer,Buffer (30ml) soya milk + 400mg sodium bicarbonate,No buffer,No buffer,Rotavirus IgA AB,60,92,65%,60/92 (65%),63,102,62%,63/102 (62%),194Clark (2003),Rotavirus,Buffer,USA,731,2.0 - 4.0,2--4,3x HRRV,"HRRV (3 doses, 42-56d apart)",1ml buffer,Concentrated buffer (1ml) sodium phosphate + citrate,No buffer,No buffer,Rotavirus IgA AB,96,108,89%,96/108 (89%),107,119,90%,107/119 (90%),227Ing (1991) **,Rotavirus,Buffer,USA,174,1.75 - 4.0,1.8--4,1x RRV-TV,RRV-TV (1 dose),25ml buffer,Buffer (25ml) sodium bicarbonate + soyabean formula,No buffer,No buffer,Rotavirus IgA AB,23,47,49%,23/47 (49%),10,44,23%,10/44 (23%),91Kerdpanich (2010),Rotavirus,Buffer,Thailand,450,2.2,2.2,2x RV1,"RV1 (2 doses, 2m apart)",1ml buffer,Buffer (1ml) water + calcium carbonate,No buffer,No buffer,Rotavirus IgA AB,133,157,85%,133/157 (85%),121,154,79%,121/154 (79%),311Ali (2014),Rotavirus,Delayed first dose,Pakistan,630,1.4,1.4,2x RV1,RV1 (2 doses),"Late (10,14w)",Late (10 & 14w),"Std (6,10w)",Std (6 & 10w),Rotavirus IgA AB,60,156,38%,60/156 (38%),46,155,30%,46/155 (30%),311Anh (2011),Rotavirus,Delayed first dose,Phillippines,375,2,2,2x RV1,RV1 (2 doses) ,"Late (11,15w)",Late (11 & 15w),"Std (7,15w)",Std (7 & 15w),Rotavirus IgA AB,84,120,70%,84/120 (70%),71,120,59%,71/120 (59%),240Armah (2016),Rotavirus,Delayed first dose,Ghana,456,1.4,1.4,2x RV1,RV1 (2 doses),"Late (10,14w)",Late (10 & 14w),"Std (6,10w)",Std (6 & 10w),Rotavirus IgA AB,52,139,37%,52/139 (37%),29,142,20%,29/142 (20%),281Steele (2010) *,Rotavirus,Delayed first dose,South Africa,150,1.5,1.5,2x RV1 + OPV,RV1 (2 doses),"Late (10,14w)",Late (10 & 14w),"Std (6,10w)",Std (6 & 10w),Rotavirus IgA AB,30,49,61%,30/49 (61%),24,67,36%,24/67 (36%),116Steele (2010) *,Rotavirus,Delayed first dose,South Africa,150,1.5,1.5,2x RV1 + IPV,RV1 (2 doses),"Late (10,14w)",Late (10 & 14w),"Std (6,10w)",Std (6 & 10w),Rotavirus IgA AB,28,51,55%,28/51 (55%),28,65,43%,28/65 (43%),116DeXiang (1986),Polio,Extra dose at birth,China,400,0.1,0.1,tOPV,"tOPV (0,2,3,4m or 2,3,4m)",4 doses,Four doses,3 doses,3 doses,OPV1 N-AB,106,107,99%,106/107 (99%),107,107,100%,107/107 (100%),214DeXiang (1986),Polio,Extra dose at birth,China,400,0.1,0.1,tOPV,"tOPV (0,2,3,4m or 2,3,4m)",4 doses,Four doses,3 doses,3 doses,OPV2 N-AB,107,107,100%,107/107 (100%),105,107,98%,105/107 (98%),214DeXiang (1986),Polio,Extra dose at birth,China,400,0.1,0.1,tOPV,"tOPV (0,2,3,4m or 2,3,4m)",4 doses,Four doses,3 doses,3 doses,OPV3 N-AB,107,107,100%,107/107 (100%),106,107,99%,106/107 (99%),214Jain (1997),Polio,Extra dose at birth,India,150,0,0,tOPV,"tOPV (0,6,10,14w or 6,10,14w)",4 doses,Four doses,3 doses,3 doses,OPV1 N-AB,23,25,92%,23/25 (92%),17,30,57%,17/30 (57%),55Jain (1997),Polio,Extra dose at birth,India,150,0,0,tOPV,"tOPV (0,6,10,14w or 6,10,14w)",4 doses,Four doses,3 doses,3 doses,OPV2 N-AB,22,25,88%,22/25 (88%),23,30,77%,23/30 (77%),55Jain (1997),Polio,Extra dose at birth,India,150,0,0,tOPV,"tOPV (0,6,10,14w or 6,10,14w)",4 doses,Four doses,3 doses,3 doses,OPV3 N-AB,18,25,72%,18/25 (72%),14,30,47%,14/30 (47%),55Khare (1993),Polio,Extra dose at birth,India,87,0,0,tOPV,"tOPV (0,6,10,14w or 6,10,14w)",4 doses,Four doses,3 doses,3 doses,OPV1 N-AB,26,30,87%,26/30 (87%),37,41,90%,37/41 (90%),71Khare (1993),Polio,Extra dose at birth,India,87,0,0,tOPV,"tOPV (0,6,10,14w or 6,10,14w)",4 doses,Four doses,3 doses,3 doses,OPV2 N-AB,27,30,90%,27/30 (90%),34,41,83%,34/41 (83%),71Khare (1993),Polio,Extra dose at birth,India,87,0,0,tOPV,"tOPV (0,6,10,14w or 6,10,14w)",4 doses,Four doses,3 doses,3 doses,OPV3 N-AB,26,30,87%,26/30 (87%),32,41,78%,32/41 (78%),71Osei-Kwasi (1995),Polio,Extra dose at birth,Ghana,452,0,0,tOPV,"tOPV (0,6,10,14w or 6,10,14w)",4 doses,Four doses,3 doses,3 doses,OPV1 N-AB,167,200,84%,167/200 (84%),147,196,75%,147/196 (75%),396Osei-Kwasi (1995),Polio,Extra dose at birth,Ghana,452,0,0,tOPV,"tOPV (0,6,10,14w or 6,10,14w)",4 doses,Four doses,3 doses,3 doses,OPV2 N-AB,182,200,91%,182/200 (91%),163,196,83%,163/196 (83%),396Osei-Kwasi (1995),Polio,Extra dose at birth,Ghana,452,0,0,tOPV,"tOPV (0,6,10,14w or 6,10,14w)",4 doses,Four doses,3 doses,3 doses,OPV3 N-AB,166,200,83%,166/200 (83%),155,196,79%,155/196 (79%),396Weckx (1992),Polio,Extra dose at birth,Brazil,85,0,0,tOPV,"tOPV (0,2,4,9m or 2,4,9m)",4 doses,Four doses,3 doses,3 doses,OPV1 N-AB,27,27,100%,27/27 (100%),26,27,96%,26/27 (96%),54Weckx (1992),Polio,Extra dose at birth,Brazil,85,0,0,tOPV,"tOPV (0,2,4,9m or 2,4,9m)",4 doses,Four doses,3 doses,3 doses,OPV2 N-AB,27,27,100%,27/27 (100%),27,27,100%,27/27 (100%),54Weckx (1992),Polio,Extra dose at birth,Brazil,85,0,0,tOPV,"tOPV (0,2,4,9m or 2,4,9m)",4 doses,Four doses,3 doses,3 doses,OPV3 N-AB,26,27,96%,26/27 (96%),20,27,74%,20/27 (74%),54Bines (2015),Rotavirus,Extra dose at birth,New Zealand,96,0.1,0.1,RV3-BB,"RV3-BB (0,6,10w or 6 & 10w)",3 doses,Three doses,2 doses,2 doses,Rotavirus IgA AB,18,26,69%,18/26 (69%),15,20,75%,15/20 (75%),46Su-Arehawaratana (1992),Cholera,Extra dose(s),Thailand,120,Adult,Adult,CVD103-HgR,CVD 103-HgR (doses 1w apart),2 doses,Two doses,1 dose,1 dose,Vibriocidal AB,23,40,58%,23/40 (58%),17,40,43%,17/40 (43%),80Jhala (1981),Polio,Extra dose(s),India,87,3.0 - 36,3--36,tOPV,tOPV (doses 6-8w apart),<=6 doses,Up to six doses,3 doses,3 doses,OPV1 N-AB,23,23,100%,23/23 (100%),67,87,77%,67/87 (77%),110Jhala (1981),Polio,Extra dose(s),India,87,3.0 - 36,3--36,tOPV,tOPV (doses 6-8w apart),<=6 doses,Up to six doses,3 doses,3 doses,OPV2 N-AB,20,23,87%,20/23 (87%),63,87,72%,63/87 (72%),110Jhala (1981),Polio,Extra dose(s),India,87,3.0 - 36,3--36,tOPV,tOPV (doses 6-8w apart),<=6 doses,Up to six doses,3 doses,3 doses,OPV3 N-AB,20,23,87%,20/23 (87%),49,87,56%,49/87 (56%),110Ali (2014),Rotavirus,Extra dose(s),Pakistan,630,1.4,1.4,RV1,"RV1 (6,10,14 or 6,10w)",6/10/14w,Three doses,10/14w,2 doses,Rotavirus IgA AB,62,169,37%,62/169 (37%),60,156,39%,60/156 (39%),325Armah (2016),Rotavirus,Extra dose(s),Ghana,456,1.4,1.4,RV1,"RV1 (6,10,14 or 6,10w)",6/10/14w,Three doses,10/14w,2 doses,Rotavirus IgA AB,62,143,43%,62/143 (43%),52,139,37%,52/139 (37%),282Kompithra (2014),Rotavirus,Extra dose(s),India,90,1.4-1.6,1.4--1.6,RV1,"RV1 (6,10,14,18,22 or 6,10,14w)",6/10/14/18/22w,Five doses,6/10/14w,3 doses,Rotavirus IgA AB,12,44,27%,12/44 (27%),15,44,34%,15/44 (34%),88Lanata (1989),Rotavirus,Extra dose(s),Peru,423,2.0 -18.0,2--18,RIT4237,RIT4237 (doses 1m apart),3 doses,Three doses,1 dose,1 dose,Rotavirus CF AB,10,71,14%,10/71 (14%),20,75,27%,20/75 (27%),146Madhi (2010) *,Rotavirus,Extra dose(s),Malawi,1773,1.4,1.4,RV1,"RV1 (6,10,14 or 10,14w)",6/10/14w,Three doses,10/14w,2 doses,Rotavirus IgA AB,24,42,57%,24/42 (57%),20,42,47%,20/42 (47%),84Madhi (2010) *,Rotavirus,Extra dose(s),South Africa,1339,1.4,1.4,RV1,"RV1 (6,10,14 or 10,14w)",6/10/14w,Three doses,10/14w,2 doses,Rotavirus IgA AB,44,66,67%,44/66 (67%),40,70,57%,40/70 (57%),136Steele (JID 2010),Rotavirus,Extra dose(s),South Africa,475,1.6,1.6,RV1,"RV1 (6,10,14 or 6,10w)",6/10/14w,Three doses,10/14w,2 doses,Rotavirus IgA AB,59,133,44%,59/133 (44%),58,131,44%,58/131 (44%),264Gotuzzo (1993),Cholera,Increased vaccine inoculum,Peru,122,314.4,Adult,1x CVD103-HgR,CVD103-HgR (1 dose),High (10^9),High potency,Std (10^8),Low potency,Vibriocidal AB,28,39,72%,28/39 (72%),19,39,49%,19/39 (49%),78Sow (2017),Cholera,Increased vaccine inoculum,Mali,150,Adult,Adult,1x CVD103-HgR,CVD103-HgR (1 dose),High (2x10^9),High potency,Std (2x10^8),Standard potency,Vibriocidal AB,40,48,83%,40/48 (83%),33,46,72%,33/46 (72%),94Su-Arehawaratana (1992),Cholera,Increased vaccine inoculum,Thailand,120,Adult,Adult,1x CVD103-HgR,CVD103-HgR (1 dose),High (5x10^9),High potency,Std (5x10^8),Standard potency,Vibriocidal AB,17,40,43%,17/40 (43%),13,39,33%,13/39 (33%),79Suharyono (1992),Cholera,Increased vaccine inoculum,Indonesia,140,60 - 108,60--108,1x CVD103-HgR,CVD103-HgR (1 dose),High (10^10) (c),High potency - centrifuged,Std (5x10^9),Standard potency,Vibriocidal AB,30,33,91%,30/33 (91%),27,31,87%,27/31 (87%),64Suharyono (1992) *,Cholera,Increased vaccine inoculum,Indonesia,140,60 - 108,60--108,1x CVD103-HgR,CVD103-HgR (1 dose),High (10^10) (f),High potency - centrifuged,Std (5x10^9),Standard potency,Vibriocidal AB,26,32,81%,26/32 (81%),21,28,75%,21/28 (75%),60Agarwal (1991),Polio,Increased vaccine inoculum,India,148,6.0 - 12.0,6--12,3x tOPV,"tOPV (3 doses, 4-6w apart)",High (0.2ml),High potency i.e. double standard amount (0.2ml),Std (0.1ml),Standard potency i.e. standard amount (0.1ml),OPV1 N-AB,27,35,77%,27/35 (77%),27,42,64%,27/42 (64%),77Agarwal (1991),Polio,Increased vaccine inoculum,India,148,6.0 - 12.0,6--12,3x tOPV,"tOPV (3 doses, 4-6w apart)",High (0.2ml),High potency i.e. double standard amount (0.2ml),Std (0.1ml),Standard potency i.e. standard amount (0.1ml),OPV2 N-AB,28,35,80%,28/35 (80%),34,42,81%,34/42 (81%),77Agarwal (1991),Polio,Increased vaccine inoculum,India,148,6.0 - 12.0 ,6--12,3x tOPV,"tOPV (3 doses, 4-6w apart)",High (0.2ml),High potency i.e. double standard amount (0.2ml),Std (0.1ml),Standard potency i.e. standard amount (0.1ml),OPV3 N-AB,21,35,60%,21/35 (60%),24,42,57%,24/42 (57%),77Chopra (1989),Polio,Increased vaccine inoculum,India,104,1.0 - 12.0,1--12,5x tOPV,"tOPV (5 doses, 4w apart)",High (0.4ml),High potency i.e. 0.4ml (10 drops),Std (0.2ml),Standard potency i.e. 0.2ml (5 drops),OPV1 N-AB,25,28,89%,25/28 (89%),30,34,88%,30/34 (88%),62Chopra (1989),Polio,Increased vaccine inoculum,India,104,1.0 - 12.0,1--12,5x tOPV,"tOPV (5 doses, 4w apart)",High (0.4ml),High potency i.e. 0.4ml (10 drops),Std (0.2ml),Standard potency i.e. 0.2ml (5 drops),OPV2 N-AB,26,28,93%,26/28 (93%),32,34,94%,32/34 (94%),62Chopra (1989),Polio,Increased vaccine inoculum,India,104,1.0 - 12.0,1--12,5x tOPV,"tOPV (5 doses, 4w apart)",High (0.4ml),High potency i.e. 0.4ml (10 drops),Std (0.2ml),Standard potency i.e. 0.2ml (5 drops),OPV3 N-AB,27,28,96%,27/28 (96%),33,34,97%,33/34 (97%),62Estivariz (2012),Polio,Increased vaccine inoculum,India,1002,7,7,1x mOPV1,mOPV1 (1 dose),High (10^6.8),High potency,Std (10^6.15),Standard potency = 10^6.15 TCID Sabin1,OPV1 N-AB,7,22,32%,7/22 (32%),5,14,36%,5/14 (36%),36Jhala (1981),Polio,Increased vaccine inoculum,India,87,3.0 - 36,3--36,3x tOPV,"tOPV (3 doses, 6-8w apart)",High (0.4ml),High potency i.e. 0.4ml (10 drops),Std (0.2ml),Single dose,OPV1 N-AB,22,25,88%,22/25 (88%),67,87,77%,67/87 (77%),112Jhala (1981),Polio,Increased vaccine inoculum,India,87,3.0 - 36,3--36,3x tOPV,"tOPV (3 doses, 6-8w apart)",High (0.4ml),High potency i.e. 0.4ml (10 drops),Std (0.2ml),Single dose,OPV2 N-AB,20,25,80%,20/25 (80%),63,87,72%,63/87 (72%),112Jhala (1981),Polio,Increased vaccine inoculum,India,87,3.0 - 36,3--36,3x tOPV,"tOPV (3 doses, 6-8w apart)",High (0.4ml),High potency i.e. 0.4ml (10 drops),Std (0.2ml),Single dose,OPV3 N-AB,14,25,56%,14/25 (56%),49,87,56%,49/87 (56%),112John (2011),Polio,Increased vaccine inoculum,India,718,0,0,2x mOPV1,"mOPV1 (2 doses, 0 & 1m)",High (10^6.7),High potency,Std (10^6),Standard potency,OPV1 N-AB,130,144,90%,130/144 (90%),132,146,90%,132/146 (90%),290Patriarca (1988),Polio,Increased vaccine inoculum,Brazil,734,9.6,9.6,1x tOPV,tOPV (1 dose),High (10^6),High potency,Std (10^6),Standard potency,OPV1 N-AB,22,44,50%,22/44 (50%),19,35,54%,19/35 (54%),79Patriarca (1988),Polio,Increased vaccine inoculum,Brazil,734,9.6,9.6,1x tOPV,tOPV (1 dose),High (10^5),High potency,Std (10^5),Standard potency,OPV2 N-AB,14,23,61%,14/23 (61%),13,22,59%,13/22 (59%),45Patriarca (1988),Polio,Increased vaccine inoculum,Brazil,734,9.6,9.6,1x tOPV,tOPV (1 dose),High (6x10^5),High potency,Std (3x10^5),Standard potency,OPV3 N-AB,31,73,42%,31/73 (42%),13,83,16%,13/83 (16%),156WHO (1995),Polio,Increased vaccine inoculum,Brazil,1395,0,0,4x tOPV,"tOPV (four doses, 0,6,10,14w)",High (2x10^6),High potency,Std (1x10^6),Standard potency Sabin 1&3,OPV1 N-AB,179,195,92%,179/195 (92%),148,176,84%,148/176 (84%),371WHO (1995),Polio,Increased vaccine inoculum,Brazil,1395,0,0,4x tOPV,"tOPV (four doses, 0,6,10,14w)",High (6x10^5),High potency,Std (3x10^5),Standard potency Sabin 1&3,OPV3 N-AB,125,195,64%,125/195 (64%),111,176,63%,111/176 (63%),371WHO (1995),Polio,Increased vaccine inoculum,Gambia,1087,0 - 1.5,0--1.5,4x tOPV,"tOPV (four doses, 2,8,16,21w)",High (2x10^6),High potency,Std (1x10^6),Standard potency Sabin 1&3,OPV1 N-AB,150,161,93%,150/161 (93%),124,159,78%,124/159 (78%),320WHO (1995),Polio,Increased vaccine inoculum,Gambia,1087,0 - 1.5,0--1.5,4x tOPV,"tOPV (four doses, 2,8,16,21w)",High (6x10^5),High potency,Std (3x10^5),Standard potency Sabin 1&3,OPV3 N-AB,115,161,71%,115/161 (71%),111,159,70%,111/159 (70%),320Cohen-Abbo (1995),Polio,Narrow dose interval,USA,108,6.0 - 10.0,6--10,3x tOPV,tOPV,4w interval,Three doses - short interval (1m apart),8w interval,Wide (8w),OPV1 N-AB,26,26,100%,26/26 (100%),24,25,96%,24/25 (96%),51Cohen-Abbo (1995),Polio,Narrow dose interval,USA,108,6.0 - 10.0,6--10,3x tOPV,tOPV,4w interval,Three doses - short interval (1m apart),8w interval,Wide (8w),OPV2 N-AB,25,25,100%,25/25 (100%),25,25,100%,25/25 (100%),50Cohen-Abbo (1995),Polio,Narrow dose interval,USA,108,6.0 - 10.0,6--10,3x tOPV,tOPV,4w interval,Three doses - short interval (1m apart),8w interval,Wide (8w),OPV3 N-AB,25,26,96%,25/26 (96%),25,25,100%,25/25 (100%),51Estivariz (2015),Polio,Narrow dose interval,Bangladesh,1000,1.4,1.4,3x bOPV,bOPV,2w interval,Three doses - short interval (2w apart),4w interval,Wide (4w),OPV1 N-AB,183,186,98%,183/186 (98%),179,184,97%,179/184 (97%),370Estivariz (2015),Polio,Narrow dose interval,Bangladesh,1000,1.4,1.4,3x bOPV,bOPV,2w interval,Three doses - short interval (2w apart),4w interval,Wide (4w),OPV3 N-AB,175,186,94%,175/186 (94%),176,184,96%,176/184 (96%),370Estivariz (2015),Polio,Narrow dose interval,Bangladesh,1000,1.4,1.4,3x mOPV1,"mOPV1 (2 doses, 0 & 1m)",2w interval,Three doses - short interval (2w apart),4w interval,Wide (4w),OPV1 N-AB,180,188,96%,180/188 (96%),178,179,99%,178/179 (99%),367Mir (2015),Polio,Narrow dose interval,Pakistan,1009,0,0,"tOPV, mOPV1","tOPV at birth, then mOPV1",1w interval,Two doses - short interval (1w apart),4w interval,Wide (4w),OPV1 N-AB,105,135,78%,105/135 (78%),129,148,87%,129/148 (87%),283Anh (2011),Rotavirus,Narrow dose interval,Vietnam,375,2,2,2x RV1,RV1,4w interval,Two doses - short interval (4w apart),8w interval,Wide (8w),Rotavirus IgA AB,73,130,56%,73/130 (56%),73,130,56%,73/130 (56%),260Asturias (2016),Polio,OPV valence,Multiple,940,1.4,1.4,3x OPV,"3 doses, 6,10,14w",bOPV,bOPV,tOPV,tOPV,OPV1 N-AB,197,198,99%,197/198 (99%),86,88,98%,86/88 (98%),286Asturias (2016),Polio,OPV valence,Multiple,940,1.4,1.4,3x OPV,"3 doses, 6,10,14w",bOPV,bOPV,tOPV,tOPV,OPV3 N-AB,195,198,98%,195/198 (98%),87,88,99%,87/88 (99%),286El-Sayed (2008),Polio,OPV valence,Egypt,530,0,0,1x OPV,1 dose at birth,mOPV1,mOPV1,tOPV,tOPV,OPV1 N-AB,128,231,55%,128/231 (55%),61,190,32%,61/190 (32%),421John (1976),Polio,OPV valence,India,79,1.5 - 10.25,1.5--10.3,1x OPV,1 dose,mOPV1,mOPV1,tOPV,tOPV,OPV1 N-AB,16,18,89%,16/18 (89%),11,26,42%,11/26 (42%),44John (2011),Polio,OPV valence,India,718,0,0,2x OPV,"2 doses, 0 & 1m",mOPV1,mOPV1,tOPV,tOPV,OPV1 N-AB,108,124,87%,108/124 (87%),80,143,56%,80/143 (56%),267John (2011),Polio,OPV valence,India,597,0,0,1x OPV,1 dose at birth,mOPV1,mOPV1,tOPV,tOPVx,OPV1 N-AB,27,173,16%,27/173 (16%),18,176,10%,18/176 (10%),349Patriarca (1988),Polio,OPV valence,Brazil,734,9.6,9.6,1x OPV,1 dose,mOPV3,mOPV3,tOPV,tOPV,OPV3 N-AB,41,79,52%,41/79 (52%),13,83,16%,13/83 (16%),162Saleem (2017),Polio,OPV valence,Pakistan,900,0,0,4x OPV,"4 doses, 0,6,10,14w",bOPV,bOPV,tOPV,tOPV,OPV1 N-AB,140,144,97%,140/144 (97%),126,134,94%,126/134 (94%),278Saleem (2017),Polio,OPV valence,Pakistan,900,0,0,4x OPV,"4 doses, 0,6,10,14w",bOPV,bOPV,tOPV,tOPV,OPV3 N-AB,135,144,94%,135/144 (94%),114,134,85%,114/134 (85%),278Sutter (2000),Polio,OPV valence,Oman,1025,9,9,1x OPV,1 dose,mOPV3,Single dose mOPV3,tOPV,Single dose tOPV (SmithKline Europe),OPV3 N-AB,189,205,92%,189/205 (92%),155,177,88%,155/177 (88%),382Sutter (2010) *,Polio,OPV valence,India,900,0,0,2x OPV,"2 doses, 0 & 1m",mOPV1,mOPV1,tOPV,tOPV,OPV1 N-AB,151,168,90%,151/168 (90%),106,168,63%,106/168 (63%),336Sutter (2010) *,Polio,OPV valence,India,900,0,0,2x OPV,"2 doses, 0 & 1m",mOPV3,mOPV3,tOPV,tOPV,OPV3 N-AB,139,165,84%,139/165 (84%),87,168,52%,87/168 (52%),333Waggie (2012),Polio,OPV valence,South Africa,800,0,0,1x OPV,1 dose at birth,mOPV1,mOPV1,tOPV,tOPV,OPV1 N-AB,141,192,73%,141/192 (73%),72,184,39%,72/184 (39%),376Waggie (2012),Polio,OPV valence,South Africa,800,0,0,1x OPV,1 dose at birth,mOPV3,mOPV3,tOPV,tOPV,OPV3 N-AB,113,195,58%,113/195 (58%),39,184,21%,39/184 (21%),379Matsuda (2011),Cholera,Probiotic,Bangladesh,128,44.1,44.1,2x WC-rBS,"WC-rBS (2 doses, 2w apart)",Bbb01 (10^9),Bifidobacterium breve 01 4x10^9 CFU probiotic,Placebo,Placebo,Vibriocidal AB,40,64,63%,40/64 (63%),47,62,76%,47/62 (76%),126DeVrese (2005) *,Polio,Probiotic,Germany,66,Adult,Adult,1x OPV1,"OPV1, OPV2 & OPV3 (1 dose D8)",LGG,Lactobacillus GG 10^10 cfu,Placebo,Placebo,OPV1 N-AB,19,21,90%,19/21 (90%),18,22,82%,18/22 (82%),43DeVrese (2005) *,Polio,Probiotic,Germany,66,Adult,Adult,1x OPV2,"OPV1, OPV2 & OPV3 (1 dose D8)",LGG,Lactobacillus GG 10^10 cfu,Placebo,Placebo,OPV2 N-AB,18,21,86%,18/21 (86%),15,22,68%,15/22 (68%),43DeVrese (2005) *,Polio,Probiotic,Germany,66,Adult,Adult,1x OPV3,"OPV1, OPV2 & OPV3 (1 dose D8)",LGG,Lactobacillus GG 10^10 cfu,Placebo,Placebo,OPV3 N-AB,12,21,57%,12/21 (57%),8,22,36%,8/22 (36%),43Isolauri (1995),Rotavirus,Probiotic,Finland,UC,4.1,4.1,1x DxRRV,DxRRV (1 dose) ,Lc ATCC,Lactobacillus casei ATCC 5x10^10 CFU,Placebo,Placebo,Rotavirus IgA AB,26,28,93%,26/28 (93%),20,27,74%,20/27 (74%),55Lazarus (2017),Rotavirus,Probiotic,India,620,1.2,1.2,1x RV1,"RV1 (2 doses, 6,10w)",LGG,Lactobacillus rhamnosus GG gelatin with 10^10 organisms,Placebo,Placebo,Rotavirus IgA AB,42,136,31%,42/136 (31%),37,135,27%,37/135 (27%),271Ciarlet (2008),Polio,RVV separated from OPV,Multiple,735,2,2,3x tOPV,RV5; tOPV,w/o RVV,Concomitant RVV & OPV,w/ RVV,Stag.,OPV1 N-AB,324,326,99%,324/326 (99%),364,368,99%,364/368 (99%),694Ciarlet (2008),Polio,RVV separated from OPV,Multiple,735,2,2,3x tOPV,RV5; tOPV,w/o RVV,Concomitant RVV & OPV,w/ RVV,Stag.,OPV2 N-AB,325,326,100%,325/326 (100%),367,368,100%,367/368 (100%),694Ciarlet (2008),Polio,RVV separated from OPV,Multiple,735,2,2,3x tOPV,RV5; tOPV,w/o RVV,Concomitant RVV & OPV,w/ RVV,Stag.,OPV3 N-AB,321,326,98%,321/326 (98%),362,368,98%,362/368 (98%),694Giammanco (1988),Polio,RVV separated from OPV,Italy,86,3,3,1x tOPV,RIT4237; tOPV,w/ placebo,Concomitant RVV & OPV,w/ RVV,OPV & placebo,OPV1 N-AB,18,21,86%,18/21 (86%),16,23,70%,16/23 (70%),44Giammanco (1988),Polio,RVV separated from OPV,Italy,86,3,3,1x tOPV,RIT4237; tOPV,w/ placebo,Concomitant RVV & OPV,w/ RVV,OPV & placebo,OPV3 N-AB,11,21,52%,11/21 (52%),6,23,26%,6/23 (26%),44Hanlon (1987),Polio,RVV separated from OPV,Gambia,433,2.5,2.5,3x tOPV,RIT4237; tOPV,w/ placebo,Concomitant RVV & OPV,w/ RVV,OPV & placebo,OPV1 N-AB,79,95,83%,79/95 (83%),68,87,78%,68/87 (78%),182Hanlon (1987),Polio,RVV separated from OPV,Gambia,433,2.5,2.5,3x tOPV,RIT4237; tOPV,w/ placebo,Concomitant RVV & OPV,w/ RVV,OPV & placebo,OPV2 N-AB,90,95,95%,90/95 (95%),82,87,94%,82/87 (94%),182Hanlon (1987),Polio,RVV separated from OPV,Gambia,433,2.5,2.5,3x tOPV,RIT4237; tOPV,w/ placebo,Concomitant RVV & OPV,w/ RVV,OPV & placebo,OPV3 N-AB,57,95,60%,57/95 (60%),45,87,52%,45/87 (52%),182Migasena (1995),Polio,RVV separated from OPV,Thailand,330,2.0 - 6.0,2--6,3x tOPV,RRV-TV; tOPV,w/ placebo,Concomitant RVV & OPV,w/ RVV,OPV & placebo,OPV1 N-AB,86,94,91%,86/94 (91%),74,88,84%,74/88 (84%),182Steele (2010) **,Polio,RVV separated from OPV,South Africa,450,1.5,1.5,2x tOPV,RV1; tOPV,w/ placebo,Concomitant RVV & OPV,w/ RVV,OPV & placebo,OPV1 N-AB,68,68,100%,68/68 (100%),52,52,100%,52/52 (100%),120Steele (2010) **,Polio,RVV separated from OPV,South Africa,450,1.5,1.5,2x tOPV,RV1; tOPV,w/ placebo,Concomitant RVV & OPV,w/ RVV,OPV & placebo,OPV2 N-AB,68,68,100%,68/68 (100%),52,52,100%,52/52 (100%),120Steele (2010) **,Polio,RVV separated from OPV,South Africa,450,1.5,1.5,2x tOPV,RV1; tOPV,w/ placebo,Concomitant RVV & OPV,w/ RVV,OPV & placebo,OPV3 N-AB,61,62,99%,61/62 (99%),49,50,98%,49/50 (98%),112Vodopija (1986),Polio,RVV separated from OPV,Yugoslavia,160,3,3,1x tOPV,RIT4237; tOPV,w/ placebo,Concomitant RVV & OPV,w/ RVV,OPV & placebo,OPV1 N-AB,21,35,60%,21/35 (60%),21,33,64%,21/33 (64%),68Vodopija (1986),Polio,RVV separated from OPV,Yugoslavia,160,3,3,1x tOPV,RIT4237; tOPV,w/ placebo,Concomitant RVV & OPV,w/ RVV,OPV & placebo,OPV3 N-AB,12,33,36%,12/33 (36%),11,29,38%,11/29 (38%),62Zaman (2009),Polio,RVV separated from OPV,Bangladesh,300,1.4,1.4,3x tOPV,RV1; tOPV,w/o RVV,Concomitant RVV & OPV,w/ RVV,OPV & placebo,OPV1 N-AB,33,35,94%,33/35 (94%),57,66,86%,57/66 (86%),101Zaman (2009),Polio,RVV separated from OPV,Bangladesh,300,1.4,1.4,3x tOPV,RV1; tOPV,w/o RVV,Concomitant RVV & OPV,w/ RVV,OPV & placebo,OPV2 N-AB,33,34,97%,33/34 (97%),67,68,99%,67/68 (99%),102Zaman (2009),Polio,RVV separated from OPV,Bangladesh,300,1.4,1.4,3x tOPV,RV1; tOPV,w/o RVV,Concomitant RVV & OPV,w/ RVV,OPV & placebo,OPV3 N-AB,22,36,61%,22/36 (61%),48,69,70%,48/69 (70%),105Ciarlet (2008),Rotavirus,RVV separated from OPV,Multiple,735,2,2,3x RV5,RV5; tOPV,w/o OPV,Concomitant RVV & OPV,w/ OPV,Stag.,Rotavirus IgA AB,319,326,98%,319/326 (98%),343,368,93%,343/368 (93%),694Giammanco (1988),Rotavirus,RVV separated from OPV,Italy,86,3,3,1x RIT4237,RIT4237; tOPV,w/ placebo,Concomitant RVV & OPV,w/ OPV,RVV & placebo,Rotavirus IgM or IgG,14,24,58%,14/24 (58%),2,23,9%,2/23 (9%),47Hanlon (1987),Rotavirus,RVV separated from OPV,Gambia,433,2.5,2.5,3x RIT4237,RIT4237; tOPV,w/IPV,Concomitant RVV & OPV,w/ OPV,RVV & IPV,Rotavirus N-AB,46,99,46%,46/99 (46%),38,86,44%,38/86 (44%),185Migasena (1995),Rotavirus,RVV separated from OPV,Thailand,330,2.0 - 6.0,2--6,3x RRV-TV,RRV-TV; tOPV,w/ placebo,Concomitant RVV & OPV,w/ OPV,RVV & IPV,Rotavirus IgA AB,25,91,27%,25/91 (27%),15,89,17%,15/89 (17%),180Steele (2010) *,Rotavirus,RVV separated from OPV,South Africa,271,1.5,1.5,"RV1 (6,10w)",RV1; tOPV,w/ placebo,Concomitant RVV & OPV,w/ OPV,RVV & IPV,Rotavirus IgA AB,28,65,43%,28/65 (43%),24,67,36%,24/67 (36%),132Steele (2010) *,Rotavirus,RVV separated from OPV,South Africa,179,1.5,1.5,"RV1 (10,14w)",RV1; tOPV,w/ placebo,Concomitant RVV & OPV,w/ OPV,RVV & IPV,Rotavirus IgA AB,28,51,55%,28/51 (55%),30,49,61%,30/49 (61%),100Vodopija (1986),Rotavirus,RVV separated from OPV,Yugoslavia,160,3,3,1x RIT4237,RIT4237; tOPV,w/ placebo,Concomitant RVV & OPV,w/ OPV,RVV & placebo,Rotavirus N-AB,19,29,66%,19/29 (66%),10,38,26%,10/38 (26%),67Zaman (2009),Rotavirus,RVV separated from OPV,Bangladesh,300,1.4,1.4,2x RV1,RV1; tOPV,w/o OPV,Concomitant RVV & OPV,w/ OPV,RVV alone,Rotavirus IgA AB,44,66,67%,44/66 (67%),39,69,57%,39/69 (57%),135Albert (2003),Cholera,Vitamin A,Bangladesh,256,40,40,2x Cholerix,"Cholerix (2 doses, 2w apart)",Vit A (200k IU),"Vitamin A (200,000 IU)",Placebo,Placebo,Vibriocidal AB,34,61,56%,34/61 (56%),29,63,46%,29/63 (46%),124Bahl (2002),Polio,Vitamin A,India,526,0.8,0.8,3x tOPV,"tOPV (3 doses 6,10,14w)",Vit A (25k IU),"Vitamin A (25,000 IU) or (RE 7.5mg) (plus maternal single-dose 60mg (18-28d post partum))",Placebo,Placebo,OPV1 N-AB,159,194,82%,159/194 (82%),146,205,71%,146/205 (71%),399Bahl (2002),Polio,Vitamin A,India,526,0.8,0.8,3x tOPV,"tOPV (3 doses 6,10,14w)",Vit A (25k IU),"Vitamin A (25,000 IU) or (RE 7.5mg) (plus maternal single-dose 60mg (18-28d post partum))",Placebo,Placebo,OPV2 N-AB,179,194,92%,179/194 (92%),191,205,93%,191/205 (93%),399Bahl (2002),Polio,Vitamin A,India,526,0.8,0.8,3x tOPV,"tOPV (3 doses 6,10,14w)",Vit A (25k IU),"Vitamin A (25,000 IU) or (RE 7.5mg) (plus maternal single-dose 60mg (18-28d post partum))",Placebo,Placebo,OPV3 N-AB,164,194,85%,164/194 (85%),165,205,80%,165/205 (80%),399Newton (2005),Polio,Vitamin A,Ghana,1085,0.9,0.9,3x tOPV,"tOPV (3 doses 6,10,14w)",Vit A (25k IU),"Vitamin A (25,000 IU) or (RE 7.5mg) ",Placebo,Placebo,OPV1 N-AB,174,192,91%,174/192 (91%),181,194,93%,181/194 (93%),386Newton (2005),Polio,Vitamin A,Ghana,1085,0.9,0.9,3x tOPV,"tOPV (3 doses 6,10,14w)",Vit A (25k IU),"Vitamin A (25,000 IU) or (RE 7.5mg) ",Placebo,Placebo,OPV2 N-AB,181,192,94%,181/192 (94%),183,194,94%,183/194 (94%),386Newton (2005),Polio,Vitamin A,Ghana,1085,0.9,0.9,3x tOPV,"tOPV (3 doses 6,10,14w)",Vit A (25k IU),"Vitamin A (25,000 IU) or (RE 7.5mg) ",Placebo,Placebo,OPV3 N-AB,171,192,89%,171/192 (89%),171,194,88%,171/194 (88%),386Rahman (1998),Polio,Vitamin A,Bangladesh,57,1.5 - 4.25,1.5--4.3,3x tOPV,"tOPV (3 doses D0, D28 & D56)",Vit A (50k IU),"Vitamin A (50,000 IU)",Placebo,Placebo,OPV1 N-AB,27,34,79%,27/34 (79%),19,23,83%,19/23 (83%),57Rahman (1998),Polio,Vitamin A,Bangladesh,57,1.5 - 4.25,1.5--4.3,3x tOPV,"tOPV (3 doses D0, D28 & D56)",Vit A (50k IU),"Vitamin A (50,000 IU)",Placebo,Placebo,OPV2 N-AB,28,34,82%,28/34 (82%),21,23,91%,21/23 (91%),57Rahman (1998),Polio,Vitamin A,Bangladesh,57,1.5 - 4.25,1.5--4.3,3x tOPV,"tOPV (3 doses D0, D28 & D56)",Vit A (50k IU),"Vitamin A (50,000 IU)",Placebo,Placebo,OPV3 N-AB,28,34,82%,28/34 (82%),20,23,87%,20/23 (87%),57Semba (1999),Polio,Vitamin A,Indonesia,467,1.7,1.7,3x tOPV,"tOPV (3 doses 6,10,14w)",Vit A (50k IU),"Vitamin A (50,000 IU)",Placebo,Placebo,OPV1 N-AB,100,102,98%,100/102 (98%),91,92,99%,91/92 (99%),194Semba (1999),Polio,Vitamin A,Indonesia,467,1.7,1.7,3x tOPV,"tOPV (3 doses 6,10,14w)",Vit A (50k IU),"Vitamin A (50,000 IU)",Placebo,Placebo,OPV2 N-AB,116,116,100%,116/116 (100%),113,113,100%,113/113 (100%),229Semba (1999),Polio,Vitamin A,Indonesia,467,1.7,1.7,3x tOPV,"tOPV (3 doses 6,10,14w)",Vit A (50k IU),"Vitamin A (50,000 IU)",Placebo,Placebo,OPV3 N-AB,113,113,100%,113/113 (100%),111,112,99%,111/112 (99%),225Ahmed (Jan 2009),Cholera,Zinc,Bangladesh,176,7.5,7.5,2x WC-rBS,"WC-rBS (2 doses, 2w apart)",Zinc (20mg),Zinc (20mg),No Zinc,No Zinc,Vibriocidal AB,11,36,31%,11/36 (31%),27,47,57%,27/47 (57%),83Ahmed (Jan 2009),Cholera,Zinc,Bangladesh,164,14,14,2x WC-rBS,"WC-rBS (2 doses, 2w apart)",Zinc (20mg),Zinc (20mg),No Zinc,No Zinc,Vibriocidal AB,27,34,79%,27/34 (79%),27,49,55%,27/49 (55%),83Ahmed (Oct 2009),Cholera,Zinc,Bangladesh,60,14,14,2x WC-rBS,"WC-rBS (2 doses, 2w apart)",Zinc (20mg),Zinc (20mg),No Zinc,No Zinc,Vibriocidal AB,15,18,83%,15/18 (83%),11,20,55%,11/20 (55%),38Albert (2003),Cholera,Zinc,Bangladesh,256,40,40,2x Cholerix,"Cholerix (2 doses, 2w apart)",Zinc (20mg),Zinc (20mg),Placebo,Placebo,Vibriocidal AB,39,63,62%,39/63 (62%),29,63,46%,29/63 (46%),126Habib (2015),Polio,Zinc,Pakistan,404,0.3,0.3,4x tOPV,"tOPV (4 doses, 0,6,10,14w)",Zinc (10mg),Zinc (10mg),Placebo,Placebo,OPV1 N-AB,136,156,87%,136/156 (87%),139,163,85%,139/163 (85%),319Habib (2015),Polio,Zinc,Pakistan,404,0.3,0.3,4x tOPV,"tOPV (4 doses, 0,6,10,14w)",Zinc (10mg),Zinc (10mg),Placebo,Placebo,OPV2 N-AB,127,156,81%,127/156 (81%),126,163,77%,126/163 (77%),319Habib (2015),Polio,Zinc,Pakistan,404,0.3,0.3,4x tOPV,"tOPV (4 doses, 0,6,10,14w)",Zinc (10mg),Zinc (10mg),Placebo,Placebo,OPV3 N-AB,94,156,60%,94/156 (60%),99,163,61%,99/163 (61%),319Lazarus (2017),Rotavirus,Zinc,India,620,1.2,1.2,2x RV1,"RV1 (2 doses, 6,10w)",Zinc (5mg),Zinc (5mg),Placebo,Placebo,Rotavirus IgA AB,40,143,28%,40/143 (28%),37,135,27%,37/135 (27%),278